SAN FRANCISCO, CA--(Marketwire - August 18, 2010) - Urigen Pharmaceuticals, Inc. (OTCQB: URGP), a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the FDA has granted the Company a Type C meeting to discuss guidance for clinical protocols of URG101, a regional therapy for Painful Bladder Syndrome/Interstitial Cystitis.
Lowell Parsons, MD, Urigen's Chief Medical Officer, said, "We are pleased the FDA has agreed to meet to discuss our URG101 program. Since Painful Bladder Syndrome/Interstitial Cystitis occurs in a discrete region of the body, there is a definite role for a regional therapy such as URG101, and it may also provide the safest approach."
About Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc. is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's two lead programs target significant unmet medical needs and major market opportunities in urology. Urigen's URG101, a proprietary combination of approved drugs that is instilled into the bladder, targets painful bladder syndrome, which affects approximately 10.5 million men and women in North America. Urigen's URG301, a proprietary dosage form of an approved drug that is locally delivered to control urinary urgency, targets acute urgency in females diagnosed with an overactive bladder, another major unmet need that is insufficiently managed by presently available overactive bladder drugs. For further information, please visit Urigen's website at http://www.urigen.com.
This press release may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Urigen has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Urigen believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Urigen does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.